Christopher Gerry - 14 Nov 2025 Form 3 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
President & PEO
Signature
/s/ Christopher Gerry
Issuer symbol
SNSE
Transactions as of
14 Nov 2025
Net transactions value
$0
Form type
3
Filing time
24 Nov 2025, 19:01:47 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gerry Christopher President & PEO C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE /s/ Christopher Gerry 24 Nov 2025 0002097951

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SNSE Common Stock 1,574 14 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SNSE Stock Option (Right to Buy) 14 Nov 2025 Common Stock 3,750 $38.20 Direct F2
holding SNSE Sock Option (Right to Buy) 14 Nov 2025 Common Stock 1,100 $28.60 Direct F3
holding SNSE Sock Option (Right to Buy) 14 Nov 2025 Common Stock 5,881 $15.70 Direct F4
holding SNSE Sock Option (Right to Buy) 14 Nov 2025 Common Stock 4,999 $9.00 Direct F5
holding SNSE Sock Option (Right to Buy) 14 Nov 2025 Common Stock 2,500 $9.52 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. 1,444 of the shares underlying the RSUs have fully vested and the remaining 130 shares vest in two equal installments on February 15, 2026 and February 15, 2027, in each case subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
F2 The shares subject to the option vest monthly over thirty-six (36) months from the vesting commencement date, July 18, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F3 The shares subject to the option vest monthly over thirty-six (36) months from the vesting commencement date, February 15, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F4 The shares subject to the option vest monthly over thirty-six (36) months from the vesting commencement date, February 15, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F5 100% of the shares subject to the option shall vest on December 1, 2025, subject to the Reporting Person's continuous service with the Issuer as of such date.
F6 The shares subject to the option vest monthly over thirty-six (36) months from the vesting commencement date, February 14, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney